Acute myeloblastic leukemia with maturation

This early-stage trial is testing an experimental drug called AMX-883, taken by mouth, for people with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. The study will first test AMX-883 alone, th…

This study tests a new chemotherapy drug, L-Annamycin, combined with standard cytarabine in adults with acute myeloid leukemia (AML) that has come back or not responded to first treatment. About 312 participants will receive either the new drug combo or a placebo plus cytarabine.…

This early-phase study is testing an experimental oral drug called AZD3632 in about 84 people with advanced blood cancers (acute leukemias or myelodysplastic syndromes) that have certain genetic changes. The main goals are to check the drug's safety and find the right dose, while…

This study looks at whether a special treatment plan for children with acute myeloid leukemia (AML) can work well in Malawi, where resources are limited. About 30 children under 18 will receive a treatment guideline designed to balance curing the disease with manageable side effe…

This study tests a combination of three drugs—tagraxofusp, azacitidine, and venetoclax—in adults with acute myeloid leukemia (AML) who are in remission but still have tiny amounts of cancer cells that standard tests miss. The goal is to see if the combo can safely clear these hid…

This study tests whether a combination of two drugs (venetoclax and low-dose cytarabine) can help adults with acute myeloid leukemia (AML) stay in remission longer. Participants are 18–60 years old, have achieved complete remission after initial chemotherapy, and are not able to …

This study is collecting blood, bone marrow, and leftover tissue samples from 550 people with acute myeloid leukemia or follicular lymphoma. Researchers will analyze the samples to find genetic markers that may predict how well treatments work or why some stop working. The goal i…